A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus

• Status: Not yet recruiting
• Trial end date: 2023-01-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of thalidomide in the treatment of refractory uremic pruritus in maintenance hemodialysis patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: RenJi Hospital
• Treatments: Thalidomide

Criteria

Inclusion Criteria:

• Maintenance hemodialysis patients (≥3 month), 3 times/week, 4 hours/session

• spKT/V≥1.2

• The diagnosis was refractory urmia pruritus and pruritus score ≥8 score

• Patients with sleep disorders need to stop sleeping pills

• Be able to complete the form by yourself or with the help of others

• Informed consent

Exclusion Criteria:

• Participants in other clinical trials within 1 month

• People with thalidomide allergy

• Accompanied by severe calcium and phosphorus metabolism disorder (serum calcium≥3.0mmol/L or Serum phosphorus≥2.8mmol/L or Serum iPTH≥800pg/mL)

• Patients with other medical conditions that cause itchy skin

• With severe systemic infection, severe anemia and other serious complications

• Patients with peripheral neuropathy

• Other serious systemic diseases include systemic lupus erythematosus, multiple myeloma, thrombotic microangiopathy, and extensive metastasis of malignant tumors

• Patients with a history of thromboembolism were excluded from PICC-induced thrombosis

• Pregnant woman